Ramucirumab for the treatment of gastroesophageal cancers

INTRODUCTION: In 2014, the U.S. Food and Drug Administration (FDA) approved ramucirumab for use in the second line setting of advanced or metastatic, gastric or gastroesophageal adenocarcinoma (GEAC) based on the result of Phase III clinical trials; REGARD and RAINBOW. AREAS COVERED: We briefly revi...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Expert Opin Orphan Drugs
Huvudupphovsmän: Shimodaira, Y., Elimova, E., Wadhwa, R., Shiozaki, H., Charalampakis, N., Planjery, V., Rogers, J.E., Song, S., Ajani, J.A.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2015
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5001688/
https://ncbi.nlm.nih.gov/pubmed/27570714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/21678707.2015.1040390
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk